Exdensur Approved by the European Commission for Severe Asthma With Type 2 Inflammation and Chronic Rhinosinusitis With Nasal Polyps
February 18, 2026
February 18, 2026
LONDON, England, Feb. 18 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Feb. 17, 2026:
* * *
Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps
* Exdensur is the first and only ultra-long-acting biologic in the EU to treat respiratory diseases
* Approval based on four phase III trials with statist . . .
* * *
Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps
* Exdensur is the first and only ultra-long-acting biologic in the EU to treat respiratory diseases
* Approval based on four phase III trials with statist . . .